CHCHD10 and myopathy: Moreover, CHCHD2’s relationship to its binding partner CHCHD10 (95, 96)—implicated in ALS, FTD, and myopathy—supports the hypothesis of shared molecular mechanisms across these disorders, as well as the potential for convergent therapeutic strategies.